Remternetug
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | LY3372993; LY-3372993 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Remternetug is an experimental anti-amyloid monoclonal antibody that targets pyroglutamate Aβ. It is developed by Eli Lilly and Company.[1][2][3][4]
References
[edit]- ^ Cummings, Jeffrey; Osse, Amanda M. Leisgang; Cammann, Davis; Powell, Jayde; Chen, Jingchun (13 November 2023). "Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease". BioDrugs. doi:10.1007/s40259-023-00633-2. PMC 10789674. PMID 37955845. S2CID 265148516.
- ^ Huang, Li-Kai; Kuan, Yi-Chun; Lin, Ho-Wei; Hu, Chaur-Jong (2 October 2023). "Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update". Journal of Biomedical Science. 30 (1): 83. doi:10.1186/s12929-023-00976-6. PMC 10544555. PMID 37784171.
- ^ Bonomi, Samuele; Samara, Amjad; Balestra, Noah; Padalia, Arjun; Benzinger, Tammie L; Kang, Peter (10 October 2023). "Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-β-Amyloid Monoclonal Antibody Treatment". Neurology. 101 (23): 1079–1080. doi:10.1212/WNL.0000000000207927. PMID 37816643.
- ^ Indig, Rinat Yona; Landau, Meytal (August 2023). "Designed inhibitors to reduce amyloid virulence and cytotoxicity and combat neurodegenerative and infectious diseases". Current Opinion in Chemical Biology. 75: 102318. doi:10.1016/j.cbpa.2023.102318. PMID 37196450. S2CID 258726675.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |